Journal article
Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients
Abstract
BACKGROUND: In the ESSENCE trial, subcutaneous low-molecular-weight heparin (enoxaparin) reduced the 30-day incidence of death, myocardial infarction, and recurrent angina relative to intravenous unfractionated heparin in 3171 patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction). No increase in major bleeding was seen.
METHODS AND RESULTS: Of the 936 ESSENCE patients randomized in the United States, 655 …
Authors
Mark DB; Cowper PA; Berkowitz SD; Davidson-Ray L; DeLong ER; Turpie AGG; Califf RM; Weatherley B; Cohen M
Journal
Circulation, Vol. 97, No. 17, pp. 1702–1707
Publisher
Wolters Kluwer
Publication Date
May 5, 1998
DOI
10.1161/01.cir.97.17.1702
ISSN
0009-7322